editoral Videos (listed by category)
CLINICAL IMPACT Series
ESMO 2023 Breast Cancer : Clinical Impact on Your Practice
Review of ESMO 2023 data in Breast Cancer with Dr. Jamil Asselah, Dr. Rami J. Younan & Dr. Kim Ma
Insights & Innovations: Panel discussion on Patient-Reported Outcomes and AI in breast cancer
With Dr. Jamil Asselah, Dr. Tarek Hijal, Pr. Sylvie Lambert, Dr. Bertrand Lebouché & John Ioculano
ASCO 2023 Breast Cancer : Clinical Impact on Your Practice
Review of ASCO 2023 data in Breast Cancer with Dr. Jamil Asselah, Dr. Nicholas Meti & Dr. Khashayar Esfahani
CLINICAL IMPACT - Genetic testing for breast cancer patients in Quebec: Why, how and whom?
Session moderated by Dr. Rami Younan, featuring Nathalie Bolduc, Genetic Counsellor and Dr. Julie Lemieux, Hematologist and Medical Oncologist.
SABCS 2022 Breast Cancer : Clinical Impact on Your Practice
Review of SABCS 2022 data in Breast Cancer with Dr. Jamil Asselah, Dr. Sara Soldera and Dr. Julie Lemieux
ESMO 2022 Breast Cancer : Clinical Impact on Your Practice
Review of ESMO 2022 data in Breast Cancer with Dr. Jamil Asselah, Dr. Rami J. Younan & Dr. Nicholas Meti
ASCO 2022 Breast Cancer : Clinical Impact on Your Practice
Review of ASCO 2022 data in Breast Cancer with Dr. Jamil Asselah, Dr. Khashayar Esfahani & Dr. Isabelle Gingras
CLINICAL IMPACT SERIES: SABCS 2021 - Breast Cancer Review Expert Panel Discussion
Presentations review with Dr. Jean-Pierre Ayoub, MD, FRCPC, Dr. Rami Younan, MD, FRCSC, and Dr. Jamil Asselah, MD, FRCPC
CLINICAL IMPACT SERIES: SABCS 2021 - Metastatic Breast Cancer
Presentations review with Dr. Jamil Asselah, MD, FRCPC
CLINICAL IMPACT SERIES: SABCS 2021 - Neo Adjuvant Breast Cancer
Presentations review with Dr. Rami Younan, MD, FRCSC
CLINICAL IMPACT SERIES: SABCS 2021 - Adjuvant Breast Cancer for ER+ HER2-, and ER-
Presentations review with Dr. Jean-Pierre Ayoub, MD, FRCPC
Dr. Tarantino - DESTINY BREAST
Q4: What is the impact of DESTINY BREAST trial on triple-negative breast cancer?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
Q3: Any other AEs to be on a look out for?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
Q2: What are the steps you take to optimally manage ILD for patients on T-DXd (The 5 S Rules)?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
Q1: In which patient profiles would you consider standard of care T-DXd for in the 2L HER2+ mBC setting? And is there a patient profile you would not consider it?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
SABCS 2023
SABCS 2023 Breast Cancer : Clinical Impact on Your Practice
Review of SABCS 2023 data in Breast Cancer with Dr. Rami Younan, Dr. Julie Lemieux & Dr. Kim Ma
SABCS 2023 : Global Speaker Series Dr. Sara A. Hurvitz
HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
SABCS 2023 : Global Speaker Series Dr. Seema Khan
Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of ECOG-ACRIN 4112
SABCS 2023 : Global Speaker Series Dr. Peter Schmid
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
SABCS 2023 : Global Speaker Series Dr. Hope S. Rugo
Essential findings of the INAVO120 primary analysis
SABCS 2023 : Global Speaker Series Dr. Shaheenah Dawood
Exploring Pioneering Initiatives: Tailoring Patient-Centric Solutions for a Diverse Cohort in the UAE
SABCS 2023 : Global Speaker Series Dr. Hatem Azim
Fertility preservation and assisted reproductive technologies in breast cancer patients interrupting adjuvant endocrine therapy to attempt pregnancy
SABCS 2023 : MedTalk Dr. Nagi S. El Saghir
Insights from the RIGHT Choice trial
SABCS 2023 : MedTalk Dr. Paolo Tarantino
Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
SABCS 2023 : Global Speaker Series Dr. Anne May
Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
SABCS 2023 : Daily RECAP Day 4 - December 8th
Daily Review from SABCS 2023 with Dr. Jamil Asselah, Dr. Esfahani, and Dr. Tarantino.
SABCS 2023 : MedTalk Dr. Julie Lemieux
Neoadjuvant chemotherapy in invasive lobular carcinoma of the breast: A retrospective study on survival outcomes
SABCS 2023 : MedTalk Dr. Jean-Pierre Ayoub
Prognostic Impact of Adjuvant Trastuzumab for the Treatment of Localized Stage I Breast Cancer - Single Tertiary Center Experience
SABCS 2023 : Daily RECAP Day 3 Part 2 - December 7th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS 2023 : Daily RECAP Day 3 Part 1 - December 7th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS 2023 : MedTalk Dr. Stephanie Wong
Evaluating chemotherapy receipt and candidacy for PARP inhibitors in germline BRCA1/2 carriers with early and locally advanced breast cancer
SABCS 2023 : MedTalk Dr. Mark Basik
Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative breast cancer and residual tumor
SABCS 2023 : Global Speaker Series Dr. Eleftherios (Terry) P. Mamounas
Loco-regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304.
SABCS 2023 : Daily Recap, December 6th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS 2023 : Global Speaker Series Dr. Claudio Vernieri
Precocious modulation of metabolic and immunological parameters predicts tumor response to fasting-mimicking diet plus chemotherapy in patients with early stage TNBC
SABCS 2023 : MedTalk Nathalie Bolduc
Key points from the SABCS session on Prevention, early detection and interception
SABCS 2023 : Global Speaker Series Barbarra Segara
Screening for health related social needs, and now what? With Barbara Segarra-Vasquez DHSc
SABCS 2023 : Global Speaker Series Dr. Carlos A. Gonzalez Nuñez
Olaparib front line therapy with endocrine therapy in locally advanced unresectable or in metastatic breast cancer: OFELIA TRIAL
SABCS 2023 : Daily Recap, December 5th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS 2022
SABCS - T-DXd Yields Longer Overall Survival than T-DM1 in Patients with HER2+ MBC
Discussion with Dr. Sara Hurvitz, M.D.
SABCS - Racial Disparity in Pro-metastatic T-MEM Among Women With Residual BC After NAC
Discussion with Dr. Maja H. Oktay, M.D., Ph.D.
SABCS 2022 - Camizestrant May Be Superior to Fulvestrant in Patients With HR+/HER2- BC
Discussion with Dr. Mafalda Oliveira, M.D., Ph.D.
SABCS 2022 : Genetic Profiling (POLAR) for Patients with BC may Safely Omit Radiation
Discussion with Pr. Per Karlsson, M.D.
SABCS 2022 - Race and Clinical Outcomes in the RxPONDER Trial
Discussion with Dr. Yara Abdou
ESMO 2022
ESMO 2022 - TROPiCS-02: Final results phase III study in MBC
Discussion with Prof. Hope S. Rugo, MD
ASCO 2022
ASCO 2022 - MAINTAIN Trial of Fulvestrant/Exemestane +/- Ribociclib After Progression in mBC
Discussion with Dr. Kevin Kalinski, MD, MS
ASCO 2022 - DESTINY-Breast04 trial in HER2-low unresectable and/or metastatic breast cancer
Pr. John Bartlett and Pr. David Cameron, MD, review the current results of DESTINY-Breast04 trial
Molecular Profiling; From prognosis to prediction – remaining questions
Scientific Presentation with Prof. John Bartlett
The success of ADCs raises questions about patient selection
Scientific Presentation with Prof. John Bartlett
AI Series
AI SERIES: Retrospective Overview Panel Discussion
Panel discussion with Faculty with Pr. Evelyne Yehudit Bischof, Professor Robert Clarke, Professor John FR Robertson
AI SERIES: Panel Discussion - Precision medicine in practice - diagnostic algorithms & geroncology
Discussion on Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES: Precision medicine in practice - diagnostic algorithms & geroncology
Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES - Panel Discussion: A review of Precision medicine in cancer therapeutics - Hormone sensitive Breast Cancer and AI challenges
Discussion on Presentation by Professor John FR Robertson MD
AI SERIES - Precision medicine cancer therapeutics, HR sensitive BC and AI challenges
Presentation by Pr. John Robertson MD
AI SERIES - AI assisted drug development and repurposing in Breast Cancer
With Dr. Evelyne Yehudit Bischof
AI SERIES - Panel discussion: Personalized vs precision medicine, clinical applicability
Discussion on Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES - Personalized vs precision medicine, clinical applicability
Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES - Panel discussion: Do we need Artificial Intelligence for Precision Medicine?
Discussion on Presentation by Pr. Robert Clarke
AI SERIES - Do we need Artificial Intelligence for Precision Medicine?
Presentation by Pr. Robert Clarke Ph.D., D.Sc.
AACR 2022
AACR 2022: Recurrent NIB May Not Always Be Related to the Primary Lesion
Interview with Dr. Tanjina Kader, PhD
AACR 2022: AI Model Can Help Predict Adverse Events from New Drug Combinations
Interview with Pr. Bart Westerman, PhD
AACR 2022: New CAR T-cell Therapy for Solid Tumors
Interview with Pr. John Haanen, MD, Ph.D
COVID Impact
Expected medium- and long-term impact of the COVID-19 on Breast Cancer Treatment in Quebec
Interview with Dr Jamil Asselah
ESMO-2020 - Expected medium and long-term impact of the COVID-19 outbreak in Oncology
Presentation by Professor Guy Jerusalem
ESMO-2020 Q&A with Professor Guy Jerusalem on Expected medium and long-term impact of the COVID-19 outbreak in Oncology
with Professor Guy Jerusalem
A Global Collaborative study looking at the Impact of COVID-19 Pandemic on Cancer Care
With Dr. Abdul-Rahman Jazieh
COVID-19 pandemic and Changes in Breast Cancer Management in the UK
With Professor John Robertson
COVID-19 pandemic and Changes in Breast Cancer Management in UK (Q&A)
With Professor John Robertson
OICR Series
Predicting Response to Anthracyclines
Presentation by Dr. Melanie Spears, PhD
Ki67 – is it ready yet?
Interview with Professor John M.S. Bartlett BSc, PhD, FRCPath
Q&A with Dr. Melanie Spears on the Characterisation of immune “hot” ER+ breast cancer
Q&A with Melanie Spears PhD
SABCS 2021
SABCS 2021 - Updated results from the phase III randomized clinical trial SWOG S1007 (RxPONDER)
Discussion with Dr. Kevin Kalinski, MD, MS
SABSC 2021 - Clinical utility of molecular tumor profiling: Results of SAFIR02-BREAST trial
Discussion with Pr Fabrice André, MD, PhD following his presentation at SABCS 2021
SABCS 2021: EMERALD phase 3 trial, Elacestrant for ER+/HER2- in mBC
SABCS 2021; Discussion with Aditya Bardia, MD, MPH,
ESMO 2021
ESMO 2021 - Overall survival (OS) results from the phase III MONALEESA-2
Discussion with Dr. Gabriel N. Hortobagyi, MD, FACP
ESMO 2021 - KEYNOTE-355: Final results phase III study in mTNBC
Discussion with Prof. Hope S. Rugo, MD
ESMO BREAST 2021 - Breast Cancer Index and prediction of extended endocrine therapy / late relapse
Interview with Professor John M.S. Bartlett BSc, PhD, FRCPath
ESMO 2021 - HER2-low breast cancer: evolution from primary breast cancer to relapse
Interview with Dr Frederica Miglietta
ASCO 2021
ASCO 2021 - Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Interview with Professor Judy E. Garber MD, MPH
SABCS 2020
SABCS 2020 - Circulating Tumor Cell Dynamics May Predict Treatment Response and Prognosis
interview with Dr. Wolfgang Janni
SABCS 2020 - First results from a phase III randomized clinical trial SWOG S1007 (RxPonder)
Interview with: Dr. Kevin Kalinsky
SABCS 2020 - 21-Gene Breast Recurrence Score® impact upon physician treatment decision in Quebec
interview with Dr. Saima Hassan
SABCS 2019
HIGHLIGHTS from SABCS: Early Breast Cancer: Partial Irradiation May be as Effective as Whole Breast Irradiation
with: Icro Meattini, MD
HIGHLIGHTS from SABCS: Interview with Andrea Hutton, breast cancer survivor, patient advocate, author
with: Andrea Hutton
HIGHLIGHTS from SABCS: ctDNA May Help Predict Recurrence in ETNBC: lack may signal improved outcomes
with: Milan Radovich, PhD
HIGHLIGHTS from SABCS: Oral Paclitaxel Yielded Better Outcomes Than Intravenous Paclitaxel for Metastatic Breast Cancer Patients in Phase III Trial
with: Gerardo Antonio Umanzor Funez, MD
HIGHLIGHTS from SABCS: The mutational landscape of cancer driver genes in matched primary DCIS and recurrent DCIS or recurrent invasive cancers.
with Jane Bayani, PhD
HIGHLIGHTS from SABCS: Breast Cancer Preventive Effects of Anastrozole Persist Long After Stopping Treatment
with: Jack Cuzick, PhD
HIGHLIGHTS from SABCS: Polygenic Breast Cancer Risk Modification in carriers of High and intermediate Risk gene Mutations
With: Allison W. Kurian, MD, MSc
HIGHLIGHTS from SABCS: Polygenic Breast Cancer Risk Modification in carriers of Risk gene Mutations
with: Elisha Hughes, PhD
HIGHLIGHTS from SABCS: Physical Activity Platforms improve bone health in cancer survivors
with: Cathy Skinner
HIGHLIGHTS from SABCS: Racial disparities in breast cancer - Identifying predisposing clinical and molecular features associated with African American patients
with: Jennifer A. Crozier, MD
HIGHLIGHTS from SABCS: APHINITY Trial - Clinical Benefit in Operable HER2-positive Early Breast Cancer patients
With: Martine Piccart, MD, PhD
HIGHLIGHTS from SABCS: KEYNOTE-522 - Neoadjuvant and Adjuvant Treatment with Pembrolizumab Improves PCR for TNBC
With: Peter Schmid, MD, PhD
HIGHLIGHTS from SABCS: Opposite Effects on Breast Cancer Incidence with Estrogen and Estrogen Plus Progestin
with: Rowan T. Chlebowski, MD, PhD
HIGHLIGHTS from SABCS: Identification of mechanisms driving acquired chemoresistance in preclinical models of taxane resistance.
with: Karen Taylor, MSc
HIGHLIGHTS from SABCS: Addition of S-1 to Post-operative Endocrine Therapy Improves Outcomes for Patients with Hormone Receptor-positive, HER2-negative Breast Cancer
with: Masakazu Toi, MD, PhD
HIGHLIGHTS from SABCS: New HER2 Antibody-drug Conjugate Yielded Promising Clinical Responses in Breast Cancer Patients Pre-treated with T-DM1
With: Ian E. Krop, MD, PhD
HIGHLIGHTS from SABCS: Phase III SOPHIA study: HER2+metastatic breast cancer interim overall survival analysis
with: Hope Rugo, M.D.
HIGHLIGHTS from SABCS: Assessing immune biomarkers of response to anthracyclines in breast cancer
with: Melanie Spears, PhD
HIGHLIGHTS from SABCS: The Genomic Landscape of Male Breast Cancers using the Oncomine Comprehensive Assay for Actionable Mutations.
with: Jane Bayani, PhD
ESMO 2019
DNA repair mutations beyond germline BRCA: Do they matter for patient management? Why treat differently?
With Juudith Balmaña
What’s needed next to meet the challenges in ER+ve breast cancer care?
A Researcher perspective
Strategies to consider to improve the slow progress in ER+ve BC and the risk of relapse
A Researcher perspective
Trans-aTTom: To offer more?
Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen.
ST.GALLEN 2019
Editorial board introductions
Processes in cancer
AACR 2022: New CAR T-cell Therapy for Solid Tumors
Interview with Pr. John Haanen, MD, Ph.D
All Editorial Videos
SABCS 2023 : Global Speaker Series Dr. Sara A. Hurvitz
HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
SABCS 2023 : Global Speaker Series Dr. Seema Khan
Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of ECOG-ACRIN 4112
SABCS 2023 : Global Speaker Series Dr. Peter Schmid
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
SABCS 2023 : Global Speaker Series Dr. Hope S. Rugo
Essential findings of the INAVO120 primary analysis
SABCS 2023 : Global Speaker Series Dr. Shaheenah Dawood
Exploring Pioneering Initiatives: Tailoring Patient-Centric Solutions for a Diverse Cohort in the UAE
SABCS 2023 : Global Speaker Series Dr. Hatem Azim
Fertility preservation and assisted reproductive technologies in breast cancer patients interrupting adjuvant endocrine therapy to attempt pregnancy
SABCS 2023 : MedTalk Dr. Nagi S. El Saghir
Insights from the RIGHT Choice trial
SABCS 2023 : MedTalk Dr. Paolo Tarantino
Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
SABCS 2023 : Global Speaker Series Dr. Anne May
Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
SABCS 2023 : Daily RECAP Day 4 - December 8th
Daily Review from SABCS 2023 with Dr. Jamil Asselah, Dr. Esfahani, and Dr. Tarantino.
SABCS 2023 : MedTalk Dr. Julie Lemieux
Neoadjuvant chemotherapy in invasive lobular carcinoma of the breast: A retrospective study on survival outcomes
SABCS 2023 : MedTalk Dr. Jean-Pierre Ayoub
Prognostic Impact of Adjuvant Trastuzumab for the Treatment of Localized Stage I Breast Cancer - Single Tertiary Center Experience
SABCS 2023 : Daily RECAP Day 3 Part 2 - December 7th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS 2023 : Daily RECAP Day 3 Part 1 - December 7th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS 2023 : MedTalk Dr. Stephanie Wong
Evaluating chemotherapy receipt and candidacy for PARP inhibitors in germline BRCA1/2 carriers with early and locally advanced breast cancer
SABCS 2023 : MedTalk Dr. Mark Basik
Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative breast cancer and residual tumor
SABCS 2023 : Global Speaker Series Dr. Eleftherios (Terry) P. Mamounas
Loco-regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304.
SABCS 2023 : Daily Recap, December 6th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS 2023 : Global Speaker Series Dr. Claudio Vernieri
Precocious modulation of metabolic and immunological parameters predicts tumor response to fasting-mimicking diet plus chemotherapy in patients with early stage TNBC
SABCS 2023 : MedTalk Nathalie Bolduc
Key points from the SABCS session on Prevention, early detection and interception
SABCS 2023 : Global Speaker Series Barbarra Segara
Screening for health related social needs, and now what? With Barbara Segarra-Vasquez DHSc
SABCS 2023 : Global Speaker Series Dr. Carlos A. Gonzalez Nuñez
Olaparib front line therapy with endocrine therapy in locally advanced unresectable or in metastatic breast cancer: OFELIA TRIAL
SABCS 2023 : Daily Recap, December 5th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS - T-DXd Yields Longer Overall Survival than T-DM1 in Patients with HER2+ MBC
Discussion with Dr. Sara Hurvitz, M.D.
SABCS - Racial Disparity in Pro-metastatic T-MEM Among Women With Residual BC After NAC
Discussion with Dr. Maja H. Oktay, M.D., Ph.D.
SABCS 2022 - Camizestrant May Be Superior to Fulvestrant in Patients With HR+/HER2- BC
Discussion with Dr. Mafalda Oliveira, M.D., Ph.D.
SABCS 2022 : Genetic Profiling (POLAR) for Patients with BC may Safely Omit Radiation
Discussion with Pr. Per Karlsson, M.D.
SABCS 2022 - Race and Clinical Outcomes in the RxPONDER Trial
Discussion with Dr. Yara Abdou
ESMO 2022 - TROPiCS-02: Final results phase III study in MBC
Discussion with Prof. Hope S. Rugo, MD
ASCO 2022 - MAINTAIN Trial of Fulvestrant/Exemestane +/- Ribociclib After Progression in mBC
Discussion with Dr. Kevin Kalinski, MD, MS
ASCO 2022 - DESTINY-Breast04 trial in HER2-low unresectable and/or metastatic breast cancer
Pr. John Bartlett and Pr. David Cameron, MD, review the current results of DESTINY-Breast04 trial
AACR 2022: Recurrent NIB May Not Always Be Related to the Primary Lesion
Interview with Dr. Tanjina Kader, PhD
AACR 2022: AI Model Can Help Predict Adverse Events from New Drug Combinations
Interview with Pr. Bart Westerman, PhD
AACR 2022: New CAR T-cell Therapy for Solid Tumors
Interview with Pr. John Haanen, MD, Ph.D
CLINICAL IMPACT SERIES: SABCS 2021 - Breast Cancer Review Expert Panel Discussion
Presentations review with Dr. Jean-Pierre Ayoub, MD, FRCPC, Dr. Rami Younan, MD, FRCSC, and Dr. Jamil Asselah, MD, FRCPC
SABCS 2021 - Updated results from the phase III randomized clinical trial SWOG S1007 (RxPONDER)
Discussion with Dr. Kevin Kalinski, MD, MS
SABSC 2021 - Clinical utility of molecular tumor profiling: Results of SAFIR02-BREAST trial
Discussion with Pr Fabrice André, MD, PhD following his presentation at SABCS 2021
SABCS 2021: EMERALD phase 3 trial, Elacestrant for ER+/HER2- in mBC
SABCS 2021; Discussion with Aditya Bardia, MD, MPH,
AI SERIES: Retrospective Overview Panel Discussion
Panel discussion with Faculty with Pr. Evelyne Yehudit Bischof, Professor Robert Clarke, Professor John FR Robertson
AI SERIES: Panel Discussion - Precision medicine in practice - diagnostic algorithms & geroncology
Discussion on Presentation by Dr. Evelyne Yehudit Bischof
ESMO 2021 - Overall survival (OS) results from the phase III MONALEESA-2
Discussion with Dr. Gabriel N. Hortobagyi, MD, FACP
ESMO 2021 - KEYNOTE-355: Final results phase III study in mTNBC
Discussion with Prof. Hope S. Rugo, MD
AI SERIES - Panel Discussion: A review of Precision medicine in cancer therapeutics - Hormone sensitive Breast Cancer and AI challenges
Discussion on Presentation by Professor John FR Robertson MD
AI SERIES - Panel Discussion: AI assisted drug development and repurposing in Breast Cancer
Discussion on Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES - Panel discussion: Personalized vs precision medicine, clinical applicability
Discussion on Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES - Panel discussion: Do we need Artificial Intelligence for Precision Medicine?
Discussion on Presentation by Pr. Robert Clarke
ASCO 2021 - Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Interview with Professor Judy E. Garber MD, MPH
Ki67 – is it ready yet?
Interview with Professor John M.S. Bartlett BSc, PhD, FRCPath
ESMO BREAST 2021 - Breast Cancer Index and prediction of extended endocrine therapy / late relapse
Interview with Professor John M.S. Bartlett BSc, PhD, FRCPath
ESMO BREAST 2021 - HER2-low breast cancer - what is it anyway?
Interview with Professor John M.S. Bartlett BSc, PhD, FRCPath
Q&A with Dr. Melanie Spears on the Characterisation of immune “hot” ER+ breast cancer
Q&A with Melanie Spears PhD
ESMO 2021 - HER2-low breast cancer: evolution from primary breast cancer to relapse
Interview with Dr Frederica Miglietta
Primary outcome analysis of invasive disease-free survival for monarchE a Quebec perspective
Interview with Dr Rami J. Younan
A Quebec clinical perspective of the randomized clinical trial SWOG S1007 (RxPonder)
Interview with Dr Jean-Francois Boileau
Expected medium- and long-term impact of the COVID-19 on Breast Cancer Treatment in Quebec
Interview with Dr Jamil Asselah
SABCS 2020 - Circulating Tumor Cell Dynamics May Predict Treatment Response and Prognosis
interview with Dr. Wolfgang Janni
SABCS 2020 - First results from a phase III randomized clinical trial SWOG S1007 (RxPonder)
Interview with: Dr. Kevin Kalinsky
SABCS 2020 - 21-Gene Breast Recurrence Score® impact upon physician treatment decision in Quebec
interview with Dr. Saima Hassan
SABCS 2020 - Primary outcome analysis of invasive disease-free survival for monarchE
With Dr. Priya Rastogi
ESMO 2020 - Q&A with Professor Stephen Johnston on results from MonarchE
with Professor Stephen Johnston
ESMO-2020 - Q&A with Dr. Susana Benerjee - The Impact of COVID-19 on Oncology Professionals: Initial Results of The ESMO Resilience Task Force Survey Collaboration
With Dr. Susana Benerjee
ESMO-2020 Q&A with Professor Guy Jerusalem on Expected medium and long-term impact of the COVID-19 outbreak in Oncology
with Professor Guy Jerusalem
COVID-19 pandemic and Changes in Breast Cancer Management in UK (Q&A)
With Professor John Robertson
HIGHLIGHTS from SABCS: Early Breast Cancer: Partial Irradiation May be as Effective as Whole Breast Irradiation
with: Icro Meattini, MD
DNA repair mutations beyond germline BRCA: Do they matter for patient management? Why treat differently?
With Juudith Balmaña
HIGHLIGHTS from SABCS: Interview with Andrea Hutton, breast cancer survivor, patient advocate, author
with: Andrea Hutton
HIGHLIGHTS from SABCS: ctDNA May Help Predict Recurrence in ETNBC: lack may signal improved outcomes
with: Milan Radovich, PhD
HIGHLIGHTS from SABCS: Oral Paclitaxel Yielded Better Outcomes Than Intravenous Paclitaxel for Metastatic Breast Cancer Patients in Phase III Trial
with: Gerardo Antonio Umanzor Funez, MD
HIGHLIGHTS from SABCS: The mutational landscape of cancer driver genes in matched primary DCIS and recurrent DCIS or recurrent invasive cancers.
with Jane Bayani, PhD
HIGHLIGHTS from SABCS: Breast Cancer Preventive Effects of Anastrozole Persist Long After Stopping Treatment
with: Jack Cuzick, PhD
HIGHLIGHTS from SABCS: Polygenic Breast Cancer Risk Modification in carriers of High and intermediate Risk gene Mutations
With: Allison W. Kurian, MD, MSc
HIGHLIGHTS from SABCS: Polygenic Breast Cancer Risk Modification in carriers of Risk gene Mutations
with: Elisha Hughes, PhD
HIGHLIGHTS from SABCS: Physical Activity Platforms improve bone health in cancer survivors
with: Cathy Skinner
HIGHLIGHTS from SABCS: Racial disparities in breast cancer - Identifying predisposing clinical and molecular features associated with African American patients
with: Jennifer A. Crozier, MD
HIGHLIGHTS from SABCS: APHINITY Trial - Clinical Benefit in Operable HER2-positive Early Breast Cancer patients
With: Martine Piccart, MD, PhD
HIGHLIGHTS from SABCS: KEYNOTE-522 - Neoadjuvant and Adjuvant Treatment with Pembrolizumab Improves PCR for TNBC
With: Peter Schmid, MD, PhD
HIGHLIGHTS from SABCS: Opposite Effects on Breast Cancer Incidence with Estrogen and Estrogen Plus Progestin
with: Rowan T. Chlebowski, MD, PhD
HIGHLIGHTS from SABCS: Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer
with: Luca Gianni, MD
HIGHLIGHTS from SABCS: Identification of mechanisms driving acquired chemoresistance in preclinical models of taxane resistance.
with: Karen Taylor, MSc
HIGHLIGHTS from SABCS: Addition of S-1 to Post-operative Endocrine Therapy Improves Outcomes for Patients with Hormone Receptor-positive, HER2-negative Breast Cancer
with: Masakazu Toi, MD, PhD
HIGHLIGHTS from SABCS: New HER2 Antibody-drug Conjugate Yielded Promising Clinical Responses in Breast Cancer Patients Pre-treated with T-DM1
With: Ian E. Krop, MD, PhD
HIGHLIGHTS from SABCS: Phase III SOPHIA study: HER2+metastatic breast cancer interim overall survival analysis
with: Hope Rugo, M.D.
HIGHLIGHTS from SABCS: Assessing immune biomarkers of response to anthracyclines in breast cancer
with: Melanie Spears, PhD
HIGHLIGHTS from SABCS: The Genomic Landscape of Male Breast Cancers using the Oncomine Comprehensive Assay for Actionable Mutations.
with: Jane Bayani, PhD
What’s needed next to meet the challenges in ER+ve breast cancer care?
A Researcher perspective
Strategies to consider to improve the slow progress in ER+ve BC and the risk of relapse
A Researcher perspective
Trans-aTTom: To offer more?
Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen.